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Rift Valley fever virus (RVFV; Bunyaviridae, Phlebovirus) causes a range of illnesses
that include retinitis, fulminant hepatitis, neurologic disease, and hemorrhagic fever.
In hospitalized individuals, case fatality rates can be as high as 10–20%. There are
no vaccines or antivirals approved for human use to prevent or treat severe RVFV
infections. We previously tested the efficacy of the MP-12 vaccine strain and related
variants with NSs truncations as a post-exposure prophylaxis in mice infected with wild-
type pathogenic RVFV strain ZH501. Post-exposure efficacy of the rMP12-C13type, a
recombinant MP-12 vaccine virus which encodes an in-frame truncation removing 69%
of the NSs protein, resulted in 30% survival when administering the virus within 30 min
of subcutaneous ZH501 challenge in mice, while the parental MP-12 virus conferred
no protection by post-exposure vaccination. Here, we demonstrate uniform protection
of hamsters by post-exposure vaccination with rMP12-C13type administered 6 h post-
ZH501 infection while no efficacy was observed with the parental MP-12 virus. Notably,
both the MP-12 and rMP12-C13type viruses were highly effective (100% protection)
when administered 21 days prior to challenge. In a subsequent study delaying vaccination
until 8, 12, and 24 h post-RVFV exposure, we observed 80, 70, and 30% survival,
respectively. Our findings indicate that the rapid protective innate immune response
elicited by rMP12-C13type may be due to the truncated NSs protein, suggesting that
the resulting functional inactivation of NSs plays an important role in the observed post-
exposure efficacy. Taken together, the data demonstrate that post-exposure vaccination
with rMP12-C13type is effective in limiting ZH501 replication and associated disease
in standard pre-exposure vaccination and post-challenge treatment models of RVFV
infection, and suggest an extended post-exposure prophylaxis window beyond that
initially observed in mice.
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Introduction
Rift Valley fever virus (RVFV) causes a devastating mosquito-
borne disease in ruminants throughout Africa and the Arabian
Peninsula, which results in abortion storms and high mortality
among young animals (Bird et al., 2009). RVFV also infects
humans via mosquito bite or exposure to animal tissues during
the processing or handling of infected animals. In humans,
the majority of individuals infected with RVFV will develop
clinical signs of an acute febrile illness characterized by fever,
malaise, and headaches with most patients recovering without
serious complications (Laughlin et al., 1979; McIntosh et al., 1980;
Madani et al., 2003). However, some cases can progress to a fatal
hemorrhagic fever syndrome, encephalitis, hepatitis, renal failure,
or retinitis that can lead to blindness.
A member of the Bunyaviridae family (genus Phlebovirus),
the enveloped RVFV possesses a tri-partite negative-sense RNA
genome that encodes seven proteins (Ikegami, 2012). The large
(L) segment encodes the RNA-dependent RNA-polymerase. The
medium (M) segment encodes the surface glycoproteins Gn and
Gc, the non-structural protein NSm, and the 78-kD protein. The
small (S) segment has an ambisense configuration and encodes
the nucleocapsid protein, N, and an additional non-structural
protein, NSs, which is transcribed from antigenomic-sense viral
RNA. NSs is considered to be a major virulence factor in the
evasion of the host cell antiviral defenses (Ikegami and Makino,
2011). NSs inhibits host transcription and the induction of
interferon (IFN)-b through specific interactions with host cell
transcription factors (Le May et al., 2004, 2008; Kalveram et al.,
2011; Kainulainen et al., 2014). The NSs protein also promotes the
degradation of double-stranded RNA-dependent protein kinase,
PKR (Habjan et al., 2009; Ikegami et al., 2009), further interfering
with host antiviral defenses by inactivating an important cytosolic
sensor of viral replication intermediates (Dauber and Wolff,
2009).
The antiviral drug, ribavirin, may be considered for treatment
of RVF, but its use is associated with toxicity and has not been
evaluated as a post-exposure prophylaxis (Borio et al., 2002).
Although many vaccine strategies have been developed to combat
RVF, none are approved for human use to prevent or treat
infections (Kortekaas, 2014). The modified live MP-12 RVFV
vaccine strain was developed by serial mutagenesis of the ZH548
strain (Caplen et al., 1985), with the partial attenuations mapped
to the S-, M-, and L-segments (Ikegami et al., 2015). It has been
extensively studied to assess safety and immunogenicity (Morrill
et al., 1987, 1991, 1997a,b; Hunter et al., 2002; Morrill and Peters,
2003; Wilson et al., 2014). We have previously described the use
of a recombinantMP-12modified vaccine virus, rMP12-C13type,
which contains an inactivating deletion in the NSs gene based
on the naturally attenuated RVFV clone 13 vaccine candidate,
(Muller et al., 1995; Dungu et al., 2010; von Teichman et al.,
2011), as a potential vaccine and post-exposure intervention in
mouse models of RVFV infection (Lihoradova et al., 2012; Gowen
et al., 2013). In the present study, we demonstrate significantly
enhanced prophylactic capacity of the rMP12-C13type vaccine
lacking functional NSs in a more rapidly progressing hamster
model of RVF disease and shed light on species variations in the
context of post-exposure vaccine efficacy and therapeutic window
in rodent infection models.
Materials and Methods
Ethics Statement
All animal procedures complied with USDA guidelines and
were conducted at the AAALAC-accredited vivarium in the
BioInnovations Building at the Utah State University Innovation
Campus under protocol 2011, approved by the Utah State
University Institutional Animal Care and Use Committee.
Animals
Female Syrian golden hamsters were obtained from Charles River
Laboratories (Wilmington, MA, USA) and quarantined for 72 h
prior to challenge or vaccination and fed Harlan Lab Block and
tap water ad libitum.
Attenuated Vaccine Viruses
The infectious clone of RVFV, strain ZH501, was obtained from
Dr. Stuart Nichol (CDC, Atlanta, GA, USA). The virus stock
[1.1 108 plaque-forming units (PFU)/ml]; BSR-T7/5, VeroE6-1,
Vero-1) used was from a clarified cell culture lysate preparation.
The virus stock was diluted in sterile minimum essential media
(MEM) and inoculated by either subcutaneous (s.c.) injection
(ventral, right side of abdomen) or intranasal (i.n.) instillation
(under isoflurane anesthesia). The MP-12 vaccine strain of RVFV
was obtained from Dr. Robert Tesh (World Reference Center for
Emerging Viruses and Arboviruses, University of Texas Medical
Branch, Galveston, TX, USA). The reverse genetics system and
rescue of the rMP-12 and rMP12-C13type recombinant vaccine
virus strains have been previously described in detail (Ikegami
et al., 2006; Kalveram et al., 2011). The recombinant vaccine
virus stocks did not contain defective interfering viral RNAs by
Northern blot analysis. All vaccine strains were diluted in sterile
phosphate buffered saline (PBS) and 0.1 ml was administered s.c.
(ventral, left side of abdomen).
Efficacy of Pre- and Post-exposure Vaccination
with rMP12-C13type and MP-12 in Hamsters
Challenged s.c. with RVFV ZH501
Five-week-old hamsters were weighed 21 days prior to infection
and grouped so that the average weight per group (n = 10 for
treatment and placebo groups, n = 3 the sham-infected group)
across the entire experiment varied by less than 5 g. Animals in
each group were treated once with PBS placebo or 1 105 PFU of
MP-12 or rMP12-C13type by s.c. injection 21 days prior or 30min,
2 or 6 h post-challenge with 30 PFU of RVFV. The hamsters were
observed for 21 days for morbidity and mortality following RVFV
ZH501 infection.
A second efficacy study was conducted in which the
vaccination was administered 8, 12, and 24 h after RVFV
ZH501 infection. For this study, 7-week-old hamsters were
weighed on the day of infection and grouped so that the average
weight per group (n= 14 for treatment and placebo groups, n= 6
the sham-infected group) across the entire experiment varied
Frontiers in Microbiology | www.frontiersin.org June 2015 | Volume 6 | Article 6512
Gowen et al. Post-exposure efficacy of rMP12-C13type vaccine
by less than 2 g. Animals were challenged s.c. with 30 PFU of
RVFV ZH501 followed by a single treatment of 1  105 PFU of
rMP12-C13type by s.c. injection at either 8, 12, or 24 h post-virus
challenge. For comparison, groups of infected animals received
the MP-12 virus or the PBS placebo by s.c. treatment at the 8 h
post-challenge time. Four animals from each treatment group
were sacrificed on day 2 of infection for analysis of viral titers.
The remaining animals were observed 28 days for morbidity and
mortality.
Efficacy of Vaccination with rMP12-C13type and
MP-12 Post-RVFV i.n. Infection
The post-exposure efficacy of rMP12-C13type vaccine was also
evaluated in the i.n. challenge hamster model. Seven-week-old
hamsterswereweighed on the day of infection and grouped so that
the averageweight per group (n= 10) across the entire experiment
varied by less than 6 g. Following i.n. instillation of 1 105 PFU of
RVFV ZH501, animals in each group were treated once with PBS
placebo or 1  105 PFU of either rMP12-C13type or rMP-12 by
s.c. injection at either 6 or 24 h post-challenge. The animals were
observed 21 days for morbidity and mortality.
Tissue and Serum Virus Titers
Virus titers were assayed using an infectious cell culture assay
as previously described (Gowen et al., 2007). Briefly, tissue
samples were homogenized in a fixed volume of MEM and the
clarified homogenates and serum were serially diluted and added
to quadruplicate wells of Vero 76 cell monolayers in 96-well
microplates. The viral cytopathic effect (CPE) was determined
7 days post-infection and the 50% endpoints were calculated
as described (Reed and Muench, 1938). The detection limit for
virus in serum was 1.49 log10 50% cell culture infectious dose
(CCID50)/ml and in tissues the lower limit of virus detection was
1.97 log10 CCID50/g of tissue.
Measurement of RNA Copy Numbers of RVFV
RNA and IFN-b mRNA
To evaluate the induction of type I IFN in hamsters by the
recombinant vaccine viruses, animals were inoculated in the
left hind footpad by s.c. injection of 0.1 ml PBS solution
containing 1  105 PFU of rMP-12, rMP12-C13type or PBS
(mock-inoculated controls). Popliteal lymph nodes (LNs) were
harvested at 24 h post-inoculation and preserved in TRI Reagent
(Sigma-Aldrich, St. Louis, MO, USA). Total RNA was extracted
from popliteal LNs and RNA concentrations weremeasured using
the Qubit 2.0 Fluorometer (Life Technologies, Grand Island, NY,
USA). First strand cDNA was synthesized from 100 ng total RNA
using iScript reverse transcriptase (Bio-Rad, Hercules, CA, USA)
and a QX100 Droplet Digital PCR System (Bio-Rad) was used
to measure RVFV S RNA and hamster IFN-b mRNA expression
according to the manufacturer’s instructions. The Taqman PCR
reaction was performed as follows: initial heating at 95°C for
10 min, 40 cycles of 30 s at 94°C and 1 min at 60°C, and the final
step at 98°C for 10 min.
RVFV S RNAwas detected by amplification of theN gene sequ-
ence with forward primer (50-GGC TGG CTG GAC ATG C-30),
reverse primer (50-AGT GAC AGG AAG CCA CTC A-30), and
probe (50-HEX-CAG GCT TTG GTC GTC TTG AG-BHQ1-30)
designed for the parental MP-12 virus. Because the sequence of
IFN-b mRNA for Syrian golden hamsters (Mesocricetus auratus)
was not available, we cloned a partial IFN-b mRNA sequence
for the Taqman probe design. For the detection of hamster IFN-
b, forward primer (50-ACC CTA AAG GAA GTG CCA GA-30),
reverse primer (50-CCA GCT GCC AGT AAT AGC TC-30), and
probe (50-HEX-AGT TTG ACT ACA AGG ATT AGC TTG AA-
BHQ1-30) were designed. Because the assay also detected the
IFN-b gene in genomic DNA as indicated by a positive signal in
theminus-reverse transcriptase (-RT) control reactions, the IFN-b
mRNAcopy number was calculated by subtraction of the genomic
IFN-b signal from the total signal in RT-containing reactions.
Statistical Analysis
The Mantel-Cox log-rank test was used for analysis of Kaplan-
Meier survival curves. A one-way analysis of variance (ANOVA)
with a Tukey post hoc test was performed to compare differences
in viral titers and RNA copy numbers. All statistical evaluations
were done using Prism (GraphPad Software, La Jolla, CA, USA).
Results
Post-exposure Vaccination with rMP12-C13type
Protects Hamsters from Lethal s.c. RVFV
Challenge
We first evaluated the efficacy of rMP12-C13type and MP-12
when administered s.c. at 30 min, 2 or 6 h after s.c. challenge with
RVFV ZH501. The rMP12-C13type vaccine conferred complete
protection against a uniformly lethal RVFV infection at all
three post-challenge treatment times (Figure 1). In contrast, the
animals that received MP-12 all succumbed to acute infection
within 3 days of challenge. Both rMP12-C13type and MP-12
provided full protection when hamsters were vaccinated 21 days
prior to challenge (data not shown). The 100% survival rate
observed with the post-exposure rMP12-C13type treatment was
unexpected based on our previous results in mice demonstrating
only partial protectionwhen administeredwithin 30min of RVFV
ZH501 challenge (Gowen et al., 2013).
Because of the dramatic efficacy observed when administered
6 h post-exposure, we next evaluated the dosing of the rMP12-
C13type vaccine at 8, 12, or 24 h post-infection (hpi) with s.c.
RVFV ZH501. As shown in Figure 2, treatment with the rMP12-
C13type virus strain significantly improved survival outcome
when compared to the placebo and MP-12-treated animals at
all three post-infection timepoints. All of the animals treated
at 8 hpi with placebo and all but one of the MP-12-treated
animals succumbed to the infection by day 3 with the last animal
expiring on day 12. Comparatively, 80% of the 8 hpi rMP12-
C13type treatment group, 70% of the 12 hpi group, and 30% of
the 24 hpi group survived the lethal challenge, suggesting that the
window for post-exposure effectiveness is not far beyond the 24
hpi treatment time.Many of the rMP12-C13type-treated hamsters
survived the acute infection, with some animals surviving well
into the 3rd week post-infection and most likely succumbing to
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FIGURE 1 | Survival of Syrian golden hamsters challenged s.c. with
RVFV then treated with rMP12-C13type or MP-12 vaccine strains.
Animals in each group (n = 10) were treated s.c. with 1  105 PFU of
rMP12-C13type or MP-12 at (A) 0.5 h, (B) 2 h, or (C) 6 h post-infection.
***P < 0.001 compared to animals that received the placebo.
late-onset neurologic disease previously described in mice treated
with rMP12-C13type virus (Gowen et al., 2013) and hamsters
protected from acute disease by antivirals (Scharton et al., 2014).
Because a detailed analysis of serum, brain, and other tissue virus
titers were not performed in the deceased or moribund animals,
wewere not able to determine if hamsters succumbing beyond day
4 post-infection (the time by which all placebo-treated animals
FIGURE 2 | Survival of hamsters challenged s.c. with RVFV that
received post-exposure treatment with rMP12-C13type or MP-12
vaccine strains. Animals in each group (n = 10) were treated s.c. with
1  105 PFU of rMP12-C13type, MP-12 or placebo at 8, 12, or 24 h
post-infection. ***P < 0.001 compared to animals receiving the placebo.
aP < 0.001, cP < 0.05 compared to animals treated with MP-12.
expire) had cleared the systemic infection with virus present only
in the brain. However, based on previous work with antiviral
treatment of RVFV infection in hamsters (Scharton et al., 2014),
we suspect that animals succumbing beyond 7 days post-RVFV
challenge had very high viral loads in the brain and associated
neurologic disease.
The effect of the post-exposure treatments on reducing viral
titers in subsets of animals sacrificed on day 2 post-infection is
shown in Figure 3. Treatment with rMP12-C13type significantly
reduced day 2 viral titers at all three timepoints in serum and
tissues compared to theMP-12 treatment at 8 hpi. The decrease in
viral loads correlated with the time of rMP12-C13type treatment
with the 8 hpi group having undetectable levels of virus in most
cases and less dramatic reductions observed in the 24 hpi group.
Notably, one animal from the MP-12 treatment group and two
from the placebo group succumbed prior to sacrifice on day 2,
further demonstrating the severity of disease in animals that did
not receive rMP12-C13type post-exposure vaccine treatment.
Efficacy of Post-exposure Vaccination with
rMP12-C13type in Hamsters Challenged
i.n. with RVFV
Exposure to RVFV can also occur through the respiratory
tract. Therefore, we also investigated the use of rMP12-C13type
treatment in this capacity. In this study, a recombinant MP-
12 virus (rMP-12) served as the comparison control for the
rMP12-C13type vaccine, and along with the PBS placebo, all
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FIGURE 3 | Analysis of serum and tissue viral titers in RVFV-infected
hamsters treated with rMP12-C13type or MP-12 vaccine strains.
Hamsters were treated as described in Figure 2 and up to four animals in
each group were sacrificed on day 2 post-infection for analysis of (A) serum,
(B) liver, and (C) spleen virus titers. One animal from the MP-12 treatment
group and two from the placebo group expired prior to sacrifice on day 2.
Unique symbols in each treatment group represent values for the same animal
across all parameters. **P < 0.01, *P < 0.05, compared to animals receiving
the placebo. aP < 0.001, bP < 0.01 cP < 0.05 compared to animals treated
with MP-12.
were administered by s.c. injection at 6 or 24 hpi with i.n.
RVFV ZH501 to model respiratory tract exposure. As shown
in Figure 4, only a weak protective effect based on extended
survival time was observed in the i.n. challenge model in
animals treated with rMP12-C13type within 6 hpi. There was
no effect of rMP12-C13type treatment when administered 24
FIGURE 4 | Effect of post-exposure treatment with rMP12-C13type or
rMP-12 vaccine strains on survival outcome in hamsters challenged
i.n. with RVFV. Animals in each group (n = 10) were treated s.c. with
1  105 PFU of rMP12-C13type or MP-12 at (A) 6 h or (B) 24 h
post-infection. ***P < 0.001 compared to animals treated with placebo.
hpi (Figure 4). Considering the highly effective post-exposure
vaccination observed in the s.c. challenge model, and the fact that
rMP12-C13type treatment was more efficacious in the mouse i.n.
infectionmodel (Gowen et al., 2013), the results were unexpected.
Measurement of Viral RNA Accumulation and
IFN-b Induction Following Vaccination
To gain insights into themechanismbywhich the rMP12-C13type
virus confers post-exposure protection, we measured RVFV S
RNAand IFN-bmRNAat 24 h post-vaccination to understand the
difference between rMP-12 and rMP12-C13type in terms of initial
viral migration into draining LNs. Groups of hamsters (n = 4)
were inoculated s.c. with 1 105 PFU of rMP-12, rMP12-C13type
or PBS (mock-inoculated controls) in the left hind footpad. At
24 h post-vaccination, popliteal LNs were collected from the left
and right legs, and total RNA was extracted for copy number
measurement of RVFV S RNA or IFN-b mRNA. The mean S
RNA copies per microgram of total popliteal LN (left side) RNA
from hamsters vaccinated with rMP-12 and rMP12-C13type were
1  103 and 5.4  103, respectively (Figure 5A). The respective
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FIGURE 5 | Accumulation of RVFV S RNA and IFN-b mRNA in popliteal
lymph nodes (LNs) of vaccinated hamsters. Hamsters were vaccinated
s.c. with 1  105 PFU of rMP-12, rMP12-C13type or PBS (mock) in the left
hind leg footpad. At 24 h post-vaccination, popliteal LNs were collected from
the left and right hind legs. The RNA copies for (A) RVFV S RNA in the left and
right popliteal LNs and for (B) IFN-b mRNA in the left popliteal LNs were
measured by droplet digital PCR. Mean values are shown. Unique symbols
represent the same animal across all parameters. The dashed line represents
the limit of detection based on a mock-vaccinated control. *P < 0.05
compared to (A) the rMP12-C13type right LN and (B) rMP-12.
contralateral popliteal LNs (right side) were also assayed as
internal controls and found to have S RNA levels below the assay
detection limits. Remarkably, only one of four hamsters from the
rMP-12 group had detectable levels of IFN-b mRNA in the left
popliteal LN, whereas all four from the rMP12-C13type group
had >2.5  103 copies per microgram of total RNA (Figure 5B).
The mock-vaccinated hamster did not have detectable values for
S RNA or IFN-b mRNA. Our results indicate that replication of
the rMP12-C13type virus more consistently induces IFN-b gene
expression compared to the rMP-12 virus at the draining LN.
Discussion
Rodent models of severe viral diseases are important tools for
the development of vaccines and therapeutics, as well as gaining
insights into the mechanisms underlying disease pathogenesis.
Mouse and hamster infection models are commonly used for
proof-of-concept and early-stage preclinical drug and vaccine
development (Smith et al., 2014). We previously reported on the
efficacy of the rMP12-C13type vaccine virus when administered
prophylactically after RVFV infection in mice (Gowen et al.,
2013). Because the post-exposure therapeutic windowwas narrow
(less than 1 h) and complete protection could not be achieved
(only 30% survival) even when the rMP12-C13type vaccine was
administered within 30 min of s.c. challenge with RVFV ZH501
(Gowen et al., 2013), we extended our investigation to include
the hamster RVFV infection model. Unexpectedly, post-infection
treatment with the same 1  105 PFU dose of rMP12-C13type
used in the mouse model studies conferred complete protection
against uniformly lethal RVFV ZH501 challenge even when
vaccination was delayed until 6 hpi. Remarkably, dosing with
rMP12-C13type 12 hpi also provided a high level of protection
(70% survival), and efficacy was still apparent when the vaccine
was given 24 hpi.
In the mouse s.c. challenge study, the animals were inoculated
with approximately 300 PFU of RVFV ZH501, with the placebo-
treated mice having succumbed 4  0.9 days post-infection
(Gowen et al., 2013). In the present study, 30 PFU of virus was
inoculated s.c. and the hamsters receiving placebo succumbed
2.4  0.5 days following challenge. It is unclear why the rMP12-
C13type vaccine was more effective against the more aggressive
peracute disease caused by RVFV ZH501 infection in hamsters.
Presumably there is greater and/or more rapid induction of type
I IFN in vaccinated hamsters eliciting a more robust antiviral
response. In mice, a direct comparison of induced type I IFN in
serum and the presence of viral antigen at the draining LN were
assessed following vaccination with rMP-12 and rMP12-C13type
(Lihoradova et al., 2012). In addition to inducing greater levels
of IFN-a, rMP12-C13type infection resulted in more efficient
migration of dermal dendritic cells into popliteal LNs after s.c.
footpad inoculation. In the present study, our results in hamsters
showed the presence of rMP12-C13type viral RNA in draining
popliteal LNs and more consistent induction of IFN-b mRNA
compared to rMP-12. In the absence of NSs, rMP12-C13type
virus replication probably triggers IFN-a/b through activation of
RIG-I-like and other viral RNA-sensing cytosolic receptors that
recognize viral RNA replication intermediates (Goubau et al.,
2013). Our findings are consistent with the ineffectiveness of
the MP-12 vaccine strain in the hamster model and suggest
that the functional NSs protein produced by the MP-12 virus
negatively affects the rapid induction of effective innate host
antiviral defenses.
Another distinguishing feature observed with our evaluation
of rMP12-C13type in the hamster model was that efficacy was
greater in animals challenged with RVFV ZH501 by the s.c.
route compared to i.n. route infection. In contrast, treatment
of mice challenged i.n. with the ZH501 virus was substantially
more effective than treatment of s.c.-infected animals (Gowen
et al., 2013). These findings in mice, and our success with
the initial post-exposure treatment studies resulting in complete
protection of hamsters against s.c. inoculation of RVFV ZH501,
heightened our expectations for post-exposure treatment of
hamsters challenged by the i.n. route. In hindsight, the limited
efficacy we observed when treating with rMP12-C13type 6
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hpi suggests that a 30 min post-exposure treatment time was
warranted and may have resulted in the 30% survival range
observed in the mouse model (Gowen et al., 2013). One must also
consider the fact that 1  105 PFU of RVFV ZH501 was required
to achieve lethality in hamsters by i.n. route infection. This higher
challenge dose and direct access to the brain through the olfactory
nerve may account for the reduced efficacy.
Collectively, our results shed light on the value of employing
more than one species during initial efficacy studies and
emphasizes the challenge of determining which model will be
more predictive of outcome in humans or animals in the case
of RVFV, which is also a significant livestock pathogen. The
data presented also further supports the notion that despite the
greater degree of attenuation with the rMP12-C13type vaccine
virus, it retains its ability to replicate sufficiently to elicit protective
adaptive immunity by a standard vaccination approach, with the
added benefit of protecting against RVFV infection in a post-
exposure setting through rapid induction of innate antiviral host
defenses.
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